Dr. Jeffrey Pradeep Raj
Associate Professor (Clinical Pharmacology)
Department of Pharmacology
Qualification: MBBS, MD, DM (Clinical Pharmacology); Karnataka Medical Council Registration no: (TMN 2013 0001044 KTK)
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
1) Teaches undergraduate and post graduate students
2) Guides undergraduate and postgraduate research
3) Consults for sample size estimation and final biostatistical analysis of student/ faculty research
4) Resource person for various workshops and conferences on research methodology, good clinical practice, statistics and recent updates in Clinical Pharmacology & therapeutics
5) Editorial Board Member, BMC Pharmacology and Toxicology Journal (2023 Impact Factor: 2.605)
6) Associate Editor, European Journal of Medical Research Journal (2023 Impact Factor: 4.2)
SUBJECTS CURRENTLY TEACHING
Subject | Semester / Year |
---|---|
Clinical Pharmacology | MD, MBBS students |
ACADEMIC QUALIFICATIONS
Degree | Specialisation | Institute | Year of passing |
---|---|---|---|
AFAMS | Clinical Pharmacology | National Academy of Medical Sciences, New Delhi | 13/11/2022 |
DM | Clinical Pharmacology | Seth G S Medical College & King Edward Memorial Hospital, Mumbai | 15/09/2021 |
MD | Pharmacology | St. Johns Medical College and Hospital, Bengaluru | 25/07/2018 |
MBA | Hospital Management | Bharathiar University | 05/2015 |
PG Diploma in Biostatistics | Biostatistics | Madurai Kamraj University | 11/2014 |
PG Diploma in Family Medicine | Family Medicine | Christian Medical College, Vellore | 09/2014 |
MBBS | Christian Medical College, Vellore | 28/03/2012 |
Experience
Institution / Organisation | Designation | Role | Tenure |
---|---|---|---|
Kasturba Medical College, Manipal (MAHE-Manipal) | Associate Professor (Div. of Clinical Pharmacology) | 10.05.2024 - present | |
Sri Ramachandra Medical College & Research Institute | Assistant Professor (Div. of Clinical Pharmacology) | 24.07.2023 – 09.05.2024 | |
Seth G.S. Medical College & K.E.M Hospital, Mumbai | Assistant Professor (Clinical Pharmacology) | 28.09.2021 – 21.07.2023 | |
Seth G.S. Medical College & K.E.M Hospital, Mumbai | Senior Resident (D.M. Resident) | 27.08.2018 – 26.08.2021 | |
St. John’s Medical College, Bangalore | PG demonstrator | 20.04.2015 – 19.04.2018 | |
CSI Hospital, Erode | Medical Officer | 03.04.2013 – 15.04.2015 | |
Christian Medical College, Vellore | Intern | 01.04.2012 – 31.03.2013 |
1. Optimising Informed CONsent in clinical trials in low- and middle-income settings: feasibility of an adapted QuinteT Recruitment Intervention (QRI) in India (OrION-I)
Principal investigator: Dr. Sangeetha Paramasivan
Co-investigator: Dr. Jeffrey Pradeep Raj
Funding agencies: UK-MRC National Institute for Health Research
Brief overview:
Clinical trials (CT) are important for scientists to find treatments for complex health problems. In India, there have been reports of ethical concerns that people taking part in trials were not aware that they were in them (eg. survivors of the Bhopal gas tragedy were recruited to clinical trials without their consent). Such Concerns led the Indian Supreme Court to halt CTs briefly in 2013.
We are a diverse group of people involved in conducting or promoting the need for ethical CTs across India and the UK. We are interested in addressing inadequate informed consent, and finding methods that will help improve it. Particularly, we would like to explore the adaptability of the QuinteT Recruitment Intervention (QRI), which has been shown to optimize recruitment to CTs while safeguarding informed consent in the UK.
2. Evaluation of Newly Designed Flu-vaccine (ENDFLU)
Principal investigator: Dr. Nithya Gogtay
Co-investigator: Dr. Jeffrey Pradeep Raj
Funding agencies: Department of Biotechnology / European Commission
Brief overview:
The ENDFLU project is aimed at designing the next generation influenza vaccines that induce broader and longer-lasting protection, including through non-virus-neutralizing (non-VN) antibody and cell-mediated immunity. Harmonised and coordinated Phase I and II clinical trials will be performed.
3. Indo-European Consortium for Next Generation Influenza Vaccine Innovation (INCENTIVE)
Principal investigator: Dr. Nithya Gogtay
Co-investigator: Dr. Jeffrey Pradeep Raj
Funding agencies: Department of Biotechnology / European Commission
Brief overview:
This includes 4 studies
a) QIV- 1: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadri) administered by the intramuscular route in elderly participants. [HMSC number: 2021-0018]
b) QIV- 2: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadri) administered by the intramuscular route in children 3-8 years old. [HMSC number: 2021-0332]
c) QIV- 3: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadri) administered by the intramuscular route in infants 6-12 months of age. [HMSC number: 2021-0333]
d) Health Economic Study: The Health Economic study is envisaged to understand the potential demand of the population for the influenza vaccine, to understand which are the characteristics of the vaccine (e.g., effectiveness or severity of the side effects) that can decrease or increase acceptance of the vaccine by the population to maximize future vaccination coverage.
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Interest
Clinical Trials/research, Clinical Pharmacology, Therapeutics, Research Methodology, Bioethics, and Biostatistics
Area of Expertise
Clinical Trials/research & Biostatistics
Area of Research
New drug and biologic development – human studies
Professional Affiliations & Contributions
1. Forum for Ethics Review Committees in India (FERCI) - Life Member
2. Research Society for studies in diabetes in India (RSSDI) - Life Member
3. Academy of Family Practitioners of India (AFPI) - Life Member
4. Indian Medical Association (IMA) - Life Member
5. Medical Students Association of India (MSAI) - Life Member
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial.
Raj JP, Maurya MR, Nair N, Marfatia H, Hadaye R, Gogtay NJ. Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial. Complement Ther Med. 2023 May;73:102934.
Safety and Efficacy of Moderately-High Dose Turmacin® (Turmerosaccharide >10% w/w) Supplementation on Joint Discomfort in Healthy Adults - A Pilot Proof-of-Concept Single Arm Study.
Raj JP, Venkatachalam S, S Amaravati R. Safety and Efficacy of Moderately-High Dose Turmacin® (Turmerosaccharide >10% w/w) Supplementation on Joint Discomfort in Healthy Adults - A Pilot Proof-of-Concept Single Arm Study. J Diet Suppl. 2023 Feb 14:1-10.
Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India.
Raj JP, Gogtay NJ, Pandey A, Kakkar AK, Shafiq N, Mekala P, Pingali U, Raju AP, Mallayasamy S, Kshirsagar NA. Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India. J Clin Pharmacol. 2022 Nov;62(11):1403-1411.
Effect of behavioural interveNtion on medication aDherence amOng elderly with Select non-communicable disEases (ENDORSE) – Pilot Randomised Controlled Trial.
Raj JP, Matthew B. Effect of behavioural interveNtion on medication aDherence amOng elderly with Select non-communicable disEases (ENDORSE) – Pilot Randomised Controlled Trial. Geriatr Gerontol Int 2020; 20: 1079–1084.
Effect of Turmacin supplementation on joint discomfort and functional outcome among healthy participants - A randomized placebo-controlled trial.
Raj JP, Venkatachalam S, Rahca P, Bhaskaran S, Amaravati RS. Raj JP, Venkatachalam S, Racha P, Bhaskaran S, Amaravati RS. Effect of Turmacin supplementation on joint discomfort and functional outcome among healthy participants - A randomized placebo-controlled trial. Complement Ther Med. 2020 Sep;53:102522
Click below to view the complete list of publications.
Books/ Book Chapter
Raj JP, Amaravati RS. Performance enhancing substances and masking agents (Doping) in sports medicine. In: Rajkumar S Amaravati, Hemanth Kumar Alladu., editors. Injuries around the knee – optimizing clinical outcomes. 1st edition. Wolters Kluwer.